Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biologic variations of tumors.

I C Henderson1

  • 1Department of Medicine, UCSF 94143.

Cancer
|April 1, 1992
PubMed
Summary

Breast cancer exhibits heterogeneous growth and metastasis, making its preclinical phase lengthy. Further research should correlate mammography screening frequency with biological variations to optimize its effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).

Breast cancer research and treatment·2008
Same author

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2005
Same author

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2003
Same author

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001
Same author

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2000
Same author

Purchasing oncology services. Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services.

Cancer·2000

Area of Science:

  • Oncology
  • Radiology
  • Medical Imaging

Background:

  • Breast cancer is characterized by significant heterogeneity in tumor growth rates and metastatic patterns.
  • The clinical progression of breast cancer is typically prolonged compared to many other malignancies.
  • Screening mammography has demonstrated efficacy in reducing breast cancer mortality, likely due to a long preclinical disease phase.

Purpose of the Study:

  • To explore the heterogeneity of breast cancer growth and metastasis.
  • To understand the prolonged preclinical phase of breast cancer.
  • To identify patient populations that benefit most from screening mammography and correlate screening frequency with biological variations.

Main Methods:

  • Review of existing literature on breast cancer tumor biology and clinical progression.
  • Analysis of data on mammography screening effectiveness across different patient demographics.
  • Exploration of potential correlations between mammography screening frequency and biological variations in breast cancer.

Main Results:

  • Breast cancer exhibits marked heterogeneity in growth dynamics and metastatic behavior.
  • The preclinical phase of breast cancer is presumed to be extensive, contributing to screening efficacy.
  • Current mammography screening protocols do not equally benefit all women, and specific subgroups are not well-defined.
  • A precise definition of patient populations who benefit more or less from periodic mammography remains elusive.

Conclusions:

  • The heterogeneity of breast cancer necessitates further investigation into personalized screening strategies.
  • Future research should prioritize the relationship between mammography screening frequency and specific biological variations within breast tumors.
  • Optimizing screening mammography effectiveness requires a deeper understanding of tumor biology and patient-specific factors.

Related Experiment Videos